Clinical Trials Logo

Post Thrombotic Syndrome clinical trials

View clinical trials related to Post Thrombotic Syndrome.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04794569 Terminated - Clinical trials for Deep Vein Thrombosis

Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome

TILE
Start date: November 15, 2021
Phase: Phase 4
Study type: Interventional

The TILE pilot study will be a multicenter, open-label, assessor-blinded RCT (randomized control trial) comparing extended LMWH (Low Molecular Weight Heparin) vs. DOAC (Direct Oral Anticoagulants) to PTS (prevent post thrombotic syndrome) in patients with DVT (Deep Vein Thrombosis).

NCT ID: NCT04103112 Terminated - Clinical trials for Deep Vein Thrombosis

Compression Hosiery to Avoid Post-Thrombotic Syndrome

CHAPS
Start date: March 5, 2020
Phase: N/A
Study type: Interventional

Patients with a deep vein thrombosis (DVT) may develop long-term symptoms, e.g. lifelong leg pain, skin changes and occasionally ulceration, known as post-thrombotic syndrome (PTS). This affects about half of people with a history of DVT. This randomised study aims to show whether the regular use of a compression stocking after DVT in the leg, prevents long-term pain, swelling and ulceration. Currently small trials show varied results and a large trial is required to answer the question.

NCT ID: NCT02512601 Terminated - Clinical trials for Post-thrombotic Syndrome

Prospective Evaluation of the QoL of Patients With PTS Who Receive Compression Therapy and Sulodexide

SQUARES
Start date: September 2015
Phase: Phase 4
Study type: Interventional

This study aims to evaluate whether, in a standardised cohort of patients with mild to moderate PTS, monitored for a sufficiently long follow-up period, quality of life measured by generic instruments and disease-specific instruments evolves favourably in this patient profile. Study objective: to evaluate the evolution of quality of life in general and in the specific context of the disease of patients who have experienced an episode of deep-vein thrombosis (DVT), are affected by post-thrombotic syndrome, are subject to compression therapy and receive an additional standard venoactive agent (sulodexide 15 mg twice daily during 6 months).